CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

Check out our PLTR stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today. PLTR - Palantir Technologies Inc ...